Limosilactobacillus reuteri prevents NAFLD progression through gut dysbiosis and the phospho-Akt/mammalian target of rapamycin/LC-3 II (p-AKT/mTOR/LC-3II) pathways, thus improving insulin resistance, increasing oxidation and subsequently decreasing liver weight and blood pressure fat accumulation [40]. Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.